Researchers at the University of North Carolina have developed a novel immunotherapy that can selectively target and destroy acute myeloid leukemia (AML) cells while leaving healthy blood tissue unharmed. The breakthrough, published in the journal Blood, addresses a major challenge in treating AML: distinguishing cancerous cells from normal ones.
The study was led by immunologist Gianpietro Dotti and hematologist Paul Armistead, who engineered immune cells to recognize and attack AML cells specifically. This approach could expand treatment options for patients with this aggressive blood cancer, which has a five-year survival rate of only about 30%.
Standard treatments for AML, such as chemotherapy, often damage healthy blood cells, leading to severe side effects. The new immunotherapy aims to minimize collateral damage by precisely targeting cancer cells. The research represents a significant step toward more effective and less toxic cancer therapies.
Further research could pave the way for advanced, side-effect-free cancer treatments. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also focused on developing innovative cancer therapies, highlighting the growing interest in this field.
The findings offer hope for AML patients, particularly those who have relapsed or are resistant to existing treatments. While the therapy is still in early stages, the researchers are optimistic about its potential. Clinical trials will be necessary to confirm its safety and efficacy in humans.
This development underscores the importance of precision medicine in oncology, where treatments are tailored to target cancer cells while preserving healthy tissue. As research progresses, such immunotherapies could become a cornerstone of cancer treatment.
